Advertisement
help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 11, No. 2, 146-151, February 2006; doi:10.1634/theoncologist.11-2-146
© 2006 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Merlano, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Merlano, M.

Alternating Chemotherapy and Radiotherapy in Locally Advanced Head and Neck Cancer: An Alternative?

Marco Merlano

Department of Clinical Oncology, S. Croce General Hospital, Cuneo, Italy

Key Words. Head and neck cancer • Chemoradiation

Correspondence: Marco Merlano, M.D., Clinical Oncology, S. Croce General Hospital, Via M. Coppino 26, 12100 Cuneo, Italy. Telephone: +390171616739 Fax: +390171616793; e-mail: mcmerlano{at}tiscali.it

Rapidly alternating chemotherapy and radiotherapy (ACR) is a minor variation of concurrent chemoradiation (CCR). This scheduling has been tested in advanced head and neck cancer and has shown superiority over standard radiation in some randomized trials with only marginally greater toxicity. This paper reviews ACR in advanced head and neck cancer. The hypothesis that this approach could have a better toxicity profile than CCR is discussed in light of the published clinical data. Efficacy is also discussed on the basis of available phase III trials. Published data indicate that rapidly alternating chemoradiation adds to toxicity less than CCR and results in comparable 3-year overall survival rates. In conclusion, ACR could be as active as, and possibly less toxic than, CCR. Comparative trials are highly recommended.




This article has been cited by other articles:


Home page
 JNCI J Natl Cancer InstHome page
J. L. Lefebvre, F. Rolland, M. Tesselaar, E. Bardet, C. R. Leemans, L. Geoffrois, P. Hupperets, L. Barzan, D. de Raucourt, D. Chevalier, et al.
Phase 3 Randomized Trial on Larynx Preservation Comparing Sequential vs Alternating Chemotherapy and Radiotherapy
J Natl Cancer Inst, February 4, 2009; 101(3): 142 - 152.
[Abstract] [Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2006 by AlphaMed Press.
Advertisement